Articles tagged with Alzheimer Disease
New research published in Lancet Neurology reveals that antipsychotic medication nearly doubles the risk of death among Alzheimer's patients over a three-year period. The study found significant increases in mortality rates for patients taking antipsychotics compared to those given oral placebos.
A new study published in The Lancet Neurology found a significant long-term risk of mortality among Alzheimer's patients prescribed antipsychotic medication. The DART-AD study revealed a substantial increase in mortality rates compared to those receiving a placebo, with survival rates at 2 years differing by as much as 30%.
Researchers used innovative brain-scan technology developed at UCLA to help diagnose brain aging, often before symptoms appear. The study combined PET scans with patient-specific information on Alzheimer's risk and found that older age correlated with higher concentrations of abnormal protein deposits in the brain.
Researchers at the Gladstone Institute of Neurological Disease discovered that collagen VI protects brain cells against amyloid-beta proteins, which are widely thought to cause Alzheimer's disease. The study found that increased collagen VI expression can effectively protect neurons against Aβ toxicity.
Researchers have made significant progress in defining the genetic signature of Alzheimer's disease, a complex neurodegenerative disorder. The study identified a new SNP on chromosome 12q13 and confirmed the known apolipoprotein E association, revealing that 50% of the genetic risk effect remains unexplained.
A new study suggests that brain starvation as we age can lead to the production of amyloid plaques, a hallmark of Alzheimer's disease. Regular exercise, managing cholesterol and hypertension, and improving blood flow to the brain may help prevent or treat the disease.
Researchers identified impaired energy metabolism as a key factor in the initiation of amyloid beta plaques in Alzheimer's disease. This discovery provides new insights into the pathogenesis of AD and highlights the potential for developing new preventative and therapeutic approaches.
Researchers have discovered that two cardiovascular proteins, SRF and myocardin, work together in the brain's blood vessels to decrease blood flow and impair amyloid beta removal. Studies in human cells and mice show that these proteins increase toxic amyloid beta levels, contributing to Alzheimer's disease.
David S. Adams, WPI professor of biology and biotechnology, has been named a fellow of the American Association for the Advancement of Science (AAAS) for his work on Alzheimer's disease in a mouse model. He has also investigated neuroprotective peptides with therapeutic applications for stroke and heart attacks.
Researchers found MRI brain scans accurately diagnose Alzheimer's disease even before symptoms interfere with daily function. The study suggests incorporating MRIs into the assessment of patients with memory problems can standardize and improve early diagnosis.
A review of nine clinical trials found that cholinesterase inhibitors significantly reduced behavioral symptoms like aggression, wandering, and paranoia in Alzheimer's disease patients. The medications are safe and produce no major side effects, making them a potential alternative to antipsychotic drugs.
A commonly used epilepsy drug, sodium valproate, has been shown to reactivate the body's defenses against amyloid beta peptide, a key component of brain plaques associated with Alzheimer's disease. This reaction may help clear plaques and prevent nerve cell death linked to dementia.
A team of CSIRO scientists has developed a rapid screening system to identify inhibitors of toxic multimers formed during Alzheimer's disease progression. Folate is shown to be beneficial in the screening system, and could lead to the discovery of new agents that may prevent or delay the onset of the disease.
A new study reveals that the brain's nerve cells can survive with damaged connections for several months before deteriorating further. The research suggests a time window in which damaged connections between brain cells could recover under the right conditions, potentially halting symptoms and allowing functional recovery.
A randomized clinical trial found that CPAP treatment improved cognitive functioning in patients with mild to moderate Alzheimer's disease and obstructive sleep apnea. The study showed significant improvement in neurological test scores after treatment, suggesting clinicians should consider implementing CPAP treatment for these patients.
Severe Alzheimer disease requires frequent monitoring by healthcare professionals to enhance quality of life. An evidence-based approach is included in the Canadian Medical Association Journal's dementia series, providing recommendations for patient care.
A Swedish study suggests that a fast food diet rich in fat and cholesterol may be a potential risk factor for Alzheimer's disease. Researchers found that mice fed such a diet developed preliminary stages of the disease, which may indicate a contributory role of dietary factors in its development.
Research from the University of Leicester reveals that nitric oxide can alter brain function, impacting neurodegenerative diseases like Alzheimer's. The finding suggests a potential new approach for treating these conditions and gaining a deeper understanding of brain function.
Researchers at UCLA discover that polyphenols in red wine can block the formation of toxic brain plaques and reduce their toxicity, potentially preventing cognitive deterioration. Human clinical trials are next to test this approach.
Researchers from Cedars-Sinai Medical Center presented several studies on brain-immune interactions, including the role of cilia in regulating hippocampal neurogenesis and the use of dendritic cells to boost anti-glioma immune responses. These findings have important implications for our understanding of the brain's immune system and p...
Scientists found that a synthetic THC-like drug can improve memory in aging rats by reducing inflammation and stimulating the formation of new brain cells. The study suggests that a safe, legal substance mimicking marijuana's properties could help prevent or delay Alzheimer's disease.
A randomized, placebo-controlled clinical trial found no significant difference in the rate of dementia among participants using Ginkgo biloba or a placebo. The study, which included over 1,500 elderly volunteers, also showed that Ginkgo biloba had no effect on the progression to dementia in individuals with mild cognitive impairment.
A large multicenter trial led by the University of Pittsburgh School of Medicine found that Ginkgo biloba extract did not reduce the risk of dementia or Alzheimer's disease in either healthy elderly individuals or those with mild cognitive impairment. The study, which involved over 3,000 participants, also showed no impact on coronary ...
A large clinical trial found that ginkgo biloba has no effect on the onset of dementia or development of Alzheimer's disease. The study tested 120 milligrams of ginkgo twice daily versus placebo in 3,069 participants and showed that it had no impact on cognitive decline or mortality.
A new study published in Neurology found that a growth hormone drug, MK-677, did not slow the symptoms of Alzheimer's disease in humans. The study involved 416 participants with mild to moderate Alzheimer's disease and showed no significant impact on disease progression despite increased levels of insulin-like growth factor-1.
Researchers at LSU Health Sciences Center have identified microRNA-146a as a crucial regulator of inflammation and disease-related neuropathology in Alzheimer's disease. The study found that miRNA-146a targets the messenger RNA of an anti-inflammatory regulator, promoting brain cell inflammation.
Researchers at Southern Methodist University identified four potent chemical compounds that slow neuron degeneration, a key cause of old-age diseases like Alzheimer's and Parkinson's. The compounds, called 3-substituted indolin-2-one derivatives, are non-toxic even at high doses, offering hope for halting neurodegenerative diseases.
Scientists have found that a genetic risk factor for Alzheimer's disease slows down the brain's ability to export toxic amyloid-beta protein. The study suggests that when ApoE4 is present, the brain becomes less efficient at removing amyloid-beta, allowing it to accumulate and increase the risk of developing the disease.
Individuals carrying the APOE4 variant have a greater risk of developing Alzheimer's disease due to slower A-beta clearance from the brain. The study found that A-beta binding to apoE4 led to substantially slower clearing of A-beta, contributing to increased disease risk.
Research shows that isoflurane, a commonly used anesthetic, can induce Alzheimer's-associated changes in mouse brains, including generation of toxic amyloid-beta protein and apoptosis. The study confirms previous laboratory findings and suggests potential risks for elderly and Alzheimer's patients.
SLU researchers found a way to get a promising treatment for Alzheimer's and stroke into the brain, reversing symptoms. They discovered a unique approach to delivering drugs past the blood-brain barrier, which had blocked treatments in the past.
A recent Indiana University study reveals that 25% of family caregivers of Alzheimer's patients visit the emergency room or are hospitalized every six months. The study emphasizes the need for a broader definition of patient to include both the individual with dementia and their caregiver.
The study finds that Pittsburgh Compound B can detect amyloid deposition in the brains of clinically older adults, potentially opening the door to early diagnosis and prevention strategies. Detailed tests show no decrease in functioning among participants with Alzheimer-associated plaques, suggesting a window of opportunity to slow or ...
A brain imaging study found that individuals with higher education levels scored higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer's disease. The study supports the 'cognitive reserve' hypothesis, which suggests that greater cognitive abilities can delay symptoms of the disease. Education was ...
Scientists found that higher education may delay cognitive decline in individuals with brain plaques associated with Alzheimer's disease, suggesting a potential 'cognitive reserve' benefit.
Researchers found that blocking Cyclophilin D and developing surrounding mitochondrial targets may be viable strategies for preventing and treating Alzheimer's disease. The study provides new insights into the mechanism underlying amyloid beta-mediated mitochondrial stress, which links to synaptic plasticity and learning/memory.
A recent study found that nicotinamide, a water-soluble vitamin, lowered levels of phosphorylated tau protein, a key player in Alzheimer's disease development. The treatment also strengthened microtubules, the scaffolding within brain cells, helping to keep neurons alive and preventing symptoms in mice with Alzheimer's disease.
A study published in Neurology found that people with Alzheimer's disease who also have diabetes are twice as likely to die sooner, while those with high blood pressure are two-and-a-half times more likely. Hispanic individuals lived four years longer than non-Hispanic whites after diagnosis.
A recent study has identified four novel genes associated with Alzheimer's disease, including a gene on chromosome 14 that may influence age of onset. The research also found connections to other diseases, such as spinocerebellar ataxia and innate immune system disorders.
Researchers found that a high-fat diet rich in animal fat and poor in omega-3s can exacerbate neurological markers for Alzheimer's disease in mice. The study suggests that diets typical of most industrialized countries may promote the development of Alzheimer's.
Researchers have discovered 3-substituted indolones with neuroprotective properties, offering promising therapeutic agents for neurodegenerative conditions. The compounds are more efficacious than existing treatments and display no cytotoxicity at high doses.
Researchers found that valproic acid improved memory and reduced brain lesions in mice with an AD-like disease. The drug also prompted damaged nerves to start repairing themselves and improved performance in memory-related tests.
Researchers discovered that using Valproic Acid as a treatment in early stages of Alzheimer's disease reverses memory deficits, reduces plaque formation and prevents brain cell death, according to a new study published in the Journal of Experimental Medicine.
Scientists at Gladstone Institute of Neurological Disease have identified a new approach to destroy amyloid-beta proteins, which are linked to Alzheimer's disease. By reducing the natural inhibitor cystatin C, they can unleash potent enzyme cathepsin B to clear AB proteins from the brain.
Researchers at UIC are developing a new drug class that targets nitric oxide delivery to the brain, aiming to slow Alzheimer's disease progression. The team proposes delivering nitric oxide via bioactive molecules to restore and protect brain function.
A study published in Neurology found that people with more education and mentally demanding occupations had significantly less brain damage from Alzheimer's disease than those with less education and less demanding jobs. Higher education was associated with a stronger brain reserve, allowing it to compensate for damage and maintain fun...
Researchers investigate how neuronal activity leads to amyloid precursor protein (APP) cleavage and the formation of fibrous plaques in Alzheimer's disease patients. Treatment with a cdk5 inhibitor reduces APP association with BACE microdomains and cleavage.
Researchers discovered specific fatty acids contributing to Alzheimer's disease progression and proposed a therapeutic strategy by inhibiting an enzyme regulating fatty acid levels. Lowering the enzyme's activity improved cognitive deficits in mouse models.
The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) has secured a three-year collaboration with Pfizer Australia, valued at over $1.1 million. The partnership aims to identify blood-based biomarkers for early diagnosis and test new disease-modifying therapies.
A study found that high-dose vitamin B supplementation had no beneficial effect on cognitive decline in individuals with mild to moderate Alzheimer's disease. However, the treatment did lower homocysteine levels, and symptoms of depression were more common in those who received the supplements.
A new study suggests that people with Alzheimer's disease may have lower blood pressure because of cognitive decline. Failing memory causes forgetfulness, which can lead to a decrease in stress-related high blood pressure.
A clinical trial by UC San Diego found that high-dose vitamin B supplements did not impact cognitive decline in Alzheimer's patients, despite lowering homocysteine levels. Symptoms of depression were more common in the high-dose group.
A new study from Emory University School of Medicine found that 55 percent of Parkinson's disease patients had insufficient levels of vitamin D. The study also showed a higher fraction of patients with the lowest levels of vitamin D, described as deficiency, in the Parkinson's group compared to Alzheimer's and healthy groups.
A study published in Archives of Neurology found that individuals with Parkinson's disease are more likely to be vitamin D deficient compared to healthy adults and those with Alzheimer's disease. The average vitamin D concentration in the group with Parkinson's disease was lower than both groups.
Dr Stephen Todd will investigate the role of beta-secretase in Alzheimer's disease using a novel blood-based assay. The study aims to determine if enzyme activity predicts disease progression and response to dementia treatment.
Researchers have developed an animal model to study the effect of small strokes on nearby neurons, finding that blockages can cause significant decreases in blood flow and death of neurons. A potential new tool for brain surgeons is being developed using optical measurements to detect and protect critical areas during surgery.
Researchers at the University of Manchester are investigating the biological causes of FTLD, a group of dementias affecting the frontal and temporal lobes. They plan to study the role of genes in regulating tau and progranulin levels in the brain, with hopes of finding future therapies.
Researchers have identified compounds that block the activity of a specific enzyme, preventing brain injury and improving survival in fruit flies with Huntington's disease. The findings could lead to better treatments for degenerative diseases such as Alzheimer's and Parkinson's.
A long-term study of Alzheimer's disease patients treated with combination therapy found significant benefits in slowing symptom progression. The results support the effectiveness of this treatment approach, which may protect brain cells from further damage.
Researchers are developing a simple blood test to diagnose Alzheimer's disease by identifying biomarkers in the blood. The study aims to provide an early and accurate diagnosis, allowing for effective treatment to be given sooner.